|
David F. Hale is one of our co-founders and has been the Chairman of our board of directors since August 2003. Mr. Hale is Chairman and Chief Executive Officer of Hale BioPharma Ventures. He served as President and Chief Executive Officer and a director of CancerVax Corporation a biopharmaceutical company from October 2000 through its merger with Micromet Inc. in 2006 where he became Chairman. He was President and Chief Executive Officer and a director of Women First HealthCare Inc. from January 1998 to May 2000. Mr. Hale served as President Chief Executive Officer Chairman and a director of Gensia Inc. a biopharmaceutical company which merged to become Gensia Sicor from May 1987 to November 1997. Prior to joining Gensia Mr. Hale was President and Chief Executive Officer and a director of Hybritech Inc. and previously held sales marketing and general management positions with Johnson & Johnson and Becton Dickinson. Mr. Hale serves as Chairman of the boards of directors of Santarus Inc. and SkinMedica Inc. specialty pharmaceutical companies and Metabasis Therapeutics Inc. a biopharmaceutical company. He also serves as a director of privately-held biotechnology and specialty pharmaceutical companies including Verus Pharmaceuticals Inc. and Conatus Pharmaceuticals. Mr. Hale is also a co-founder and member of the boards of directors of industry organizations including BIOCOM/San Diego the California Healthcare Institute and CONNECT and is a member of the boards of directors of the Biotechnology Industry Organization and Rady Children’s Hospital the San Diego Economic Development Corporation and the Biotechnology Institute. Mr. Hale received a Bachelor of Arts degree in Biology and Chemistry from Jacksonville State University. | 